Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which drug wins? trial pits terlipressin against octreotide for kidney crisis

NCT ID NCT07460908

Disease control Sponsor: Lahore General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two medicines, terlipressin and octreotide, for treating hepatorenal syndrome—a serious kidney complication of advanced liver disease. Sixty adults aged 30 to 70 will receive one of the drugs, and doctors will check kidney function after 48 hours to see which works better. The goal is to find a more effective treatment to improve survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
terlipressin and octreotide
What this could lead to
If one drug works better, it could become the preferred treatment for hepatorenal syndrome, helping more patients recover kidney function quickly.
What could go wrong
This is a small, single-center trial with only 60 participants. Results may not apply to all patients, and neither drug may prove clearly superior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

May 2025

Finished

Oct 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 30 to 70 years * Either gender * Diagnosed with hepatorenal syndrome Exclusion Criteria: * Hepatocellular carcinoma * Septic shock * Cardiac failure * Respiratory failure * Stroke * Coronary artery disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatorenal syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury hepatorenal syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatorenal syndrome

Contacts and locations

Locations

  • Lahore General Hospital, Lahore

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.